Table 3.
The pooled results of comparison between TAVR and SAVR for severe AS regarding to the 30-day outcomes.
| Pooled results | Heterogeneity | ||||||
| Subgroups | No. of study/pts | RR | 95% CI | P | I2 | Ph | Analytical effect model |
| Myocardial infarction | 5/5441 | 0.62 | 0.40–0.97 | .04 | 0% | .79 | Fixed-effects model |
| Cardiogenic shock | 2/1936 | 0.34 | 0.19–0.59 | .0002 | 0% | .64 | Fixed-effects model |
| AKI >2 | 4/5371 | 0.37 | 0.25–0.54 | <.0001 | 0% | .64 | Fixed-effects model |
| Permanent PM | 5/5441 | 3.16 | 1.61–6.21 | .0008 | 90% | <.0001 | Random-effect model |
| Major vascular complications | 4/5371 | 2.22 | 1.14–4.32 | .02 | 77% | .004 | Random-effect model |
| All-cause mortality | 6/6098 | 0.87 | 0.65–1.16 | .34 | 8% | .36 | Fixed-effects model |
| CV mortality | 4/4038 | 1.04 | 0.71–1.51 | .85 | 0% | .75 | Fixed-effects model |
| Stroke | 5/5441 | 0.82 | 0.64–1.04 | .10 | 0% | .42 | Fixed-effects model |
| TIA | 5/5441 | 1.50 | 0.85–2.66 | .16 | 0% | .66 | Fixed-effects model |
| Bleeding | 5/5441 | 0.51 | 0.20–1.28 | .15 | 96% | <.0001 | Random-effect model |
| Neurological events | 2/2308 | 0.99 | 0.72–1.37 | .96 | 0% | .94 | Fixed-effects model |
| Endocarditis | 3/3711 | 1.57 | 0.21–11.80 | .66 | 0% | .61 | Fixed-effects model |
| CAD | 3/5095 | 1.37 | 0.60–3.16 | .45 | 13% | .32 | Fixed-effects model |
| Reintervention | 3/5095 | 2.66 | 1.01–7.00 | .05 | 20% | .29 | Fixed-effects model |
| Rehospitalization | 3/5095 | 0.85 | 0.66–1.11 | .24 | 46% | .16 | Fixed-effects model |
AKI = acute kidney injury, AS = aortic stenosis, CAD = coronary artery disease, CI = confidence interval, CV = cardiovascular, LVEF = left ventricular ejection fraction, NOAF = new-onset atrial fibrillation, PM = pacemaker, RF = renal failure, RR = risk ratio, SAVR = surgical aortic valve replacement, TAVR = transcatheter aortic valve replacement, TIA = transient ischemic attacks.